NOTE TO READERS: When this project lost substantial funding at the end of 2018, I lost the ability to continue publishing criteria-driven news story reviews and PR news release reviews - once the bread-and-butter of the site going back to 2006. The 3,200 archived reviews, while still educational, are getting old and difficult for me to technically maintain on the back end of the website. So I am announcing that I plan to remove these reviews from the site by April 1, 2021. The blog and the toolkit - two of the most popular features on the site - will remain. If you wish to peruse the reviews before they disappear, please do so by the end of March 2021. After that date you may still be able to access them via the Internet Archive Wayback Machine -

Tags: cancer


Newsweek trumpets an ‘aggressive’ new cancer drug, but where’s the data?


Are bacteria useful as cancer ‘weapons,’ or far too early to know? Key context missing from HealthDay story

3 8/10/2018

When n=1, it’s easy to jump to conclusions about a therapy working

1 11/28/2017

Patient anecdote outweighs data in AP’s look at lymph node transfer surgery


Washington Post wisely quantifies severe side effects and deaths from CAR-T cell therapy


TIME’s look at new heart drug overlooks high price and potentially fatal risks


In coverage of anti-inflammatory heart drug from Novartis, Reuters keeps it real


NBC News doesn’t back away from shortcomings of new blood test for early cancer detection


Newsweek presents a mostly balanced account of family’s unconventional cancer journey


Washington Post wisely notes that CAR T-cell therapy may cost at least $300,000